Abhijeet Anand, Khalequ Zaman, Concepción F. Estívariz, Mohammad Yunus et al.
Introduction: Inactivated poliovirus vaccine (IPV) introduction and phased oral poliovirus vaccine (OPV) cessation are essential for eradication of polio. Methods: Healthy 6-week old infants in Bangladesh were randomized to one of five study arms: receipt of trivalent OPV (tOPV) or bivalent OPV (bOP...
Devy Emperador, Daniel E. Velásquez, Concepción F. Estívariz, Ben Lopman et al.
BACKGROUND: Trivalent oral poliovirus vaccine (OPV) is known to interfere with monovalent rotavirus vaccine (RV1) immunogenicity. The interference caused by bivalent and monovalent OPV formulations, which will be increasingly used globally in coming years, has not been examined. We conducted a post ...
Cynthia J. Snider, Khalequ Zaman, Concepción F. Estívariz, Mohammad Yunus et al.
Background Intradermal administration of fractional inactivated poliovirus vaccine (fIPV) is a dose-sparing alternative to intramuscular full dose. We assessed the recommendation of two fIPV doses or one IPV dose for routine immunization, and a fIPV booster dose for outbreak response. Methods We con...
Leora R. Feldstein, Sarah D. Bennett, Concepción F. Estívariz, Gretchen Cooley et al.
BACKGROUND: During August 2017-January 2018, more than 700,000 forcibly displaced Rohingyas crossed into Cox's Bazar, Bangladesh. In response to measles and diphtheria cases, first documented in September and November 2017, respectively, vaccination campaigns targeting children <15 years old were mo...
Concepción F. Estívariz, Abhijeet Anand, Howard E. Gary, Mahmudur Rahman et al.
Background The provision of several doses of monovalent type 1 oral poliovirus vaccine (mOPV1) and bivalent OPV1 and 3 (bOPV) vaccines through campaigns is essential to stop the circulation of remaining wild polioviruses. Our study aimed to assess the shortening of intervals between campaigns with b...
Amanda L. Wilkinson, Khalequ Zaman, Masuma Hoque, Concepción F. Estívariz et al.
Background Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine-derived poliovirus type 2 outbreaks. Bivalent oral poliovirus vaccine (bOPV; containing Sabin types 1 and 3) is the vac...
Mallick Masum Billah, K. Zaman, Concepción F. Estívariz, Cynthia J. Snider et al.
Background: Introduction of inactivated polio vaccine creates challenges in maintaining the cold chain for vaccine storage and distribution. Methods: We evaluated the cold chain in 23 health facilities and 36 outreach vaccination sessions in 8 districts and cities of Bangladesh, using purposive samp...
Khalequ Zaman, Concepción F. Estívariz, Michelle Morales, Mohammad Yunus et al.
Background Monovalent type 2 oral poliovirus vaccine (mOPV2) and inactivated poliovirus vaccine (IPV) are used to respond to type 2 poliovirus outbreaks. We aimed to assess the effect of two mOPV2 doses on the type 2 immune response by varying the time interval between mOPV2 doses and IPV co-adminis...
Concepción F. Estívariz, Cynthia J. Snider, Abhijeet Anand, Lee M. Hampton et al.
Background: We assessed programmatic adaptations and infants' uptake of inactivated poliovirus vaccine (IPV) after its introduction into the routine immunization schedule in Bangladesh. Methods: Using convenience and probability sampling, we selected 23 health facilities, 36 vaccinators, and 336 car...
Gretchen Cooley, Leora R. Feldstein, Sarah D. Bennett, Concepción F. Estívariz et al.
Successful achievement of global targets for elimination of trachoma as a public health problem and eradication of yaws will require control efforts to reach marginalized populations, including refugees. Testing for serologic evidence of transmission of trachoma and yaws in residents of registered c...
Khalequ Zaman, Stéphanie Kovacs, Kristin VanderEnde, Asma Binte Aziz et al.
Background: After global oral poliovirus vaccine (OPV) cessation, the Strategic Advisory Group of Experts on Immunization (SAGE) currently recommends a two-dose schedule of inactivated poliovirus vaccine (IPV) beginning ≥14-weeks of age to achieve at least 90% immune response. We aimed to compare th...
Concepción F. Estívariz, Sarah D. Bennett, Jacquelyn S. Lickness, Leora R. Feldstein et al.
BACKGROUND: We performed a cross-sectional survey in April-May 2018 among Rohingya in Cox's Bazar, Bangladesh, to assess polio immunity and inform vaccination strategies. METHODS AND FINDINGS: Rohingya children aged 1-6 years (younger group) and 7-14 years (older group) were selected using multi-sta...
Cynthia J. Snider, Khalequ Zaman, Amanda L. Wilkinson, Asma Binte Aziz et al.
Background: To inform response strategies, we examined type 1 humoral and intestinal immunity induced by 1) one fractional inactivated poliovirus vaccine (fIPV) dose given with monovalent oral poliovirus vaccine (mOPV1), and 2) mOPV1 versus bivalent OPV (bOPV). Methods: We conducted a randomized, co...
Cynthia J. Snider, Khalequ Zaman, Concepción F. Estívariz, Asma Binte Aziz et al.
In 2012, the Strategic Advisory Group of Experts on Immunization (SAGE) recommended introduction of at least one inactivated poliovirus vaccine (IPV) dose in essential immunization programs. We evaluated systemic humoral and intestinal mucosal immunity of a sequential IPV-bivalent oral poliovirus va...